News
FECCIA
Other
How the industry can navigate through a particularly challenging environment
The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles. On the other hand, expiring patents, increasing competition, cost pressure, falling productivity in R&D and the uncertainties of the US government are putting the viability of the business model to the test.
Merck to Acquire US Biopharma Company SpringWorks Therapeutics
Merck KGaA and SpringWorks Therapeutics, Inc., a Stamford, Connecticut-based commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the companies have entered into a definitive agreement for Merck to acquire SpringWorks.